Novo Nordisk A/S (NVO)
48.07
+0.43
(+0.90%)
USD |
NYSE |
Jun 26, 16:00
48.03
-0.04
(-0.08%)
After-Hours: 20:00
Novo Nordisk Cash and Short Term Investments (Quarterly) : 3.335B for March 31, 2026
Cash and Short Term Investments (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 3.335B |
| December 31, 2025 | 4.240B |
| September 30, 2025 | 5.129B |
| June 30, 2025 | 2.979B |
| March 31, 2025 | 6.016B |
| December 31, 2024 | 3.653B |
| September 30, 2024 | 11.21B |
| June 30, 2024 | 9.004B |
| March 31, 2024 | 1.347B |
| December 31, 2023 | 4.480B |
| September 30, 2023 | 6.758B |
| June 30, 2023 | 5.335B |
| March 31, 2023 | 4.050B |
| December 31, 2022 | 3.383B |
| September 30, 2022 | 4.937B |
| June 30, 2022 | 4.363B |
| March 31, 2022 | 3.013B |
| December 31, 2021 | 2.673B |
| September 30, 2021 | 5.516B |
| June 30, 2021 | 4.340B |
| March 31, 2021 | 1.211B |
| December 31, 2020 | 2.097B |
| September 30, 2020 | 4.014B |
| June 30, 2020 | 3.748B |
| March 31, 2020 | 1.436B |
| Date | Value |
|---|---|
| December 31, 2019 | 2.325B |
| September 30, 2019 | 2.739B |
| June 30, 2019 | 2.206B |
| March 31, 2019 | 1.362B |
| December 31, 2018 | 2.396B |
| September 30, 2018 | 2.593B |
| June 30, 2018 | 2.983B |
| March 31, 2018 | 2.102B |
| December 31, 2017 | 3.412B |
| September 30, 2017 | 3.449B |
| June 30, 2017 | 3.542B |
| March 31, 2017 | 2.599B |
| December 31, 2016 | 3.011B |
| September 30, 2016 | 2.586B |
| June 30, 2016 | 2.361B |
| March 31, 2016 | 1.570B |
| December 31, 2015 | 3.023B |
| September 30, 2015 | 2.708B |
| June 30, 2015 | 1.825B |
| March 31, 2015 | 1.070B |
| December 31, 2014 | 2.589B |
| September 30, 2014 | 2.313B |
| June 30, 2014 | 1.238B |
| March 31, 2014 | 1.128B |
| December 31, 2013 | 2.953B |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| AstraZeneca PLC | 7.675B |
| GSK Plc | 4.540B |
| Johnson & Johnson | 22.05B |
| Eli Lilly & Co. | 5.282B |
| Merck & Co., Inc. | 5.773B |